Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Activating mutations in epidermal growth factor receptor (EGFR) are common in non-small cell lung cancer (NSCLC).
• Acquired resistance to EGFR inhibitors often involves secondary EGFR mutations or c-Met amplification.
• Existing therapies lack potent dual inhibitors to address combined EGFR and c-Met mediated resistance.

Purpose of the Study:

• To identify and design novel dual inhibitors targeting both EGFR and c-Met.
• To develop compounds capable of overcoming resistance mechanisms in NSCLC.
• To evaluate the efficacy of these dual inhibitors in preclinical models.

Main Methods:

• Design and synthesis of N-[4-(quinolin-4-yloxy)-phenyl]-biarylsulfonamide derivatives.
• In vitro kinase assays to determine inhibitory activity against wild-type and mutant EGFR, and c-Met.
• Western blot analysis to assess EGFR and c-Met phosphorylation inhibition in NSCLC cell lines.
• Cell viability assays to evaluate the anti-cancer effects of the compounds.

Main Results:

• Novel biarylsulfonamide derivatives were identified as potent dual EGFR/c-Met inhibitors.
• Compounds exhibited nanomolar inhibitory activity against wild-type and mutant EGFR, and c-Met.
• Compound 10 demonstrated inhibition of EGFR and c-Met phosphorylation and reduced NSCLC cell viability.

Conclusions:

• Novel dual EGFR/c-Met inhibitors have been successfully designed and synthesized.
• These compounds effectively inhibit key signaling pathways implicated in NSCLC resistance.
• The developed inhibitors represent promising candidates for overcoming acquired resistance in NSCLC and warrant further clinical development.